Büchler T, Nohejlová Medková A, Kupec M, Bláha M, Pavlík T, Dušek L, Abrahámová J
Onkologicka klinika1. LF UK a Thomayerovy nemocnice, Praha.
Klin Onkol. 2012;25(6):440-4.
The aim of our study was to compare healthcare-related costs of treatment with XELOX and FOLFOX4 chemotherapeutic regimens in patients with colorectal cancer. We have evaluated costs claimed to the health insurance by the hospital administering these cancer therapies. This study is a pilot project utilising the new I-COP database developed by the Institute of Biostatistics and Analyses of the Masaryk University in Brno, Czech Republic.
First, we estimated the costs based on current prices of procedures, medication, and materials from public sources. Using the I-COP database, we then carried out a matched-pair comparison of 26 patients treated with FOLFOX4 or XELOX for colorectal cancer. We evaluated a period of three months of therapy (i.e. 6 cycles of FOLFOX4 or 4 cycles of XELOX). Statistical analysis was done using the Wilcoxon matched pairs test.
The estimated cost for three months of therapy was 148,288 Czech crowns (CZK) for FOLFOX4 (including CZK 101,064 for chemotherapy drugs) and CZK 123,756 for XELOX. The overall costs claimed to the insurance companies were CZK 160,158 and CZK 151,176 for FOLFOX4 and XELOX, respectively (p = 0.221). The XELOX regimen had significantly higher costs for chemotherapy drugs (CZK 131,705 versus 114,531, p = 0.023) whereas other costs were lower than those for FOLFOX4.
FOLFOX4 and XELOX regimens can be considered as equivalent in terms of costs claimed by the hospital administering cancer treatment.
我们研究的目的是比较结直肠癌患者接受XELOX和FOLFOX4化疗方案的医疗相关费用。我们评估了实施这些癌症治疗的医院向健康保险申报的费用。本研究是一个试点项目，利用了捷克共和国布尔诺马萨里克大学的生物统计学与分析研究所开发的新I-COP数据库。
首先，我们根据公共来源的手术、药物和材料的当前价格估算费用。然后，利用I-COP数据库，我们对26例接受FOLFOX4或XELOX治疗的结直肠癌患者进行了配对比较。我们评估了三个月的治疗期（即FOLFOX4的6个周期或XELOX的4个周期）。使用Wilcoxon配对检验进行统计分析。
FOLFOX4三个月治疗期的估算费用为148,288捷克克朗（CZK）（包括化疗药物101,064捷克克朗），XELOX为123,756捷克克朗。向保险公司申报的总费用中，FOLFOX4为160,158捷克克朗，XELOX为151,176捷克克朗（p = 0.221）。XELOX方案的化疗药物费用显著更高（131,705捷克克朗对114,531捷克克朗，p = 0.023），而其他费用低于FOLFOX4。
就实施癌症治疗的医院申报的费用而言，FOLFOX4和XELOX方案可被视为等效。
